role
noninvas
ventil
niv
acut
respiratori
failur
caus
viral
pneumonia
remain
controversi
object
evalu
use
niv
cohort
v
pneumonia
use
success
niv
assess
prospect
last
decad
two
viral
pandem
signific
impact
worldwid
health
result
mainli
sever
acut
respiratori
failur
arf
first
sever
acut
respiratori
syndrom
sar
virul
clinic
entiti
high
mortal
rate
second
influenza
v
accord
report
caus
death
within
first
season
use
noninvas
ventil
niv
adult
prove
effect
treat
chronic
obstruct
pulmonari
diseas
exacerb
cardiogen
pulmonari
oedema
arf
immunocompromis
patient
patient
niv
achiev
signific
reduct
rate
endotrach
intub
ventilatorassoci
complic
improv
surviv
rate
nevertheless
metaanalys
argu
use
niv
arf
offer
advantag
convent
ventil
moreov
delay
intub
hypoxaem
intub
patient
pneumonia
may
increas
risk
complic
earli
use
niv
ard
caus
viral
pneumonia
controversi
tri
assess
clinician
use
techniqu
whether
success
perform
secondari
analysi
gteisemicyuc
grupo
de
trabajo
de
enfermedad
infecciosassociedad
de
medicina
intensiva
unidad
coronaria
registri
larg
cohort
patient
admit
intens
care
unit
icu
respiratori
failur
caus
pandem
influenza
v
pneumonia
secondari
object
assess
niv
use
might
increas
mortal
intub
subsequ
requir
patient
niv
could
predict
success
hypothes
use
niv
patient
arf
pandem
viral
pneumonia
might
effect
case
might
avoid
need
invas
mechan
ventil
data
studi
obtain
voluntari
registri
creat
node
director
jordi
rello
ciber
pci
neumonia
recruit
investig
gtei
semicyuc
studi
group
coordin
rafael
zaragoza
inclus
criteria
adult
viral
pneumonia
patient
age
year
febril
acut
ill
respiratori
symptom
cough
sore
throat
myalgia
influenzalik
ill
arf
convent
oxygen
therapi
maintain
spo
requir
icu
admiss
microbiolog
confirm
pandem
influenza
v
realtim
pcr
data
report
attend
physician
review
medic
chart
radiolog
laboratori
record
within
first
h
icu
admiss
patient
exacerb
chronic
obstruct
pulmonari
diseas
acut
pulmonari
oedema
acut
asthma
alreadi
intub
icu
admiss
use
niv
palli
use
rescu
therapi
exclud
analysi
studi
approv
institut
review
board
joan
xxiii
univers
hospit
tarragona
spain
patient
identif
remain
anonym
requir
inform
consent
waiv
observ
natur
studi
icu
admiss
criteria
treatment
decis
patient
includ
determin
need
intub
type
antibiot
antivir
therapi
administ
standard
made
attend
physician
nasopharyngealswab
specimen
collect
admiss
respiratori
secret
also
obtain
intub
patient
revers
transcriptionpcr
test
perform
accord
cdc
protocol
http
test
perform
institut
central
refer
laboratori
avail
confirm
case
defin
acut
respiratori
ill
laboratoryconfirm
pandem
viru
infect
realtim
revers
transcriptionpcr
viral
cultur
confirm
case
includ
current
studi
follow
inform
record
demograph
data
comorbid
time
ill
onset
hospit
admiss
time
first
dose
antivir
deliveri
microbiolog
find
chest
xray
find
icu
admiss
intub
mechan
ventil
requir
invas
noninvas
medic
complic
icu
stay
laboratori
find
icu
admiss
also
record
chronic
obstruct
pulmonari
diseas
defin
diseas
state
character
presenc
airflow
limit
chronic
bronchiti
emphysema
airflow
obstruct
could
accompani
airway
hyperreact
could
partial
revers
determin
sever
ill
acut
physiolog
chronic
health
evalu
apach
ii
score
record
patient
within
h
icu
admiss
addit
organ
failur
assess
use
sequenti
organ
failur
assess
sofa
score
system
definit
communityacquir
pneumonia
base
current
american
thorac
societi
infecti
diseas
societi
america
guidelin
primari
viral
pneumonia
defin
patient
acut
phase
influenza
viru
ill
present
acut
respiratori
distress
unequivoc
alveolar
opac
neg
respiratori
blood
bacteri
cultur
secondari
bacteri
pneumonia
consid
patient
confirm
influenza
viru
infect
show
recurr
fever
increas
cough
product
purul
sputum
plu
posit
bacteri
respiratori
blood
cultur
respiratori
cultur
base
tracheal
aspir
obtain
immedi
intub
acut
renal
failur
defin
need
renal
replac
therapi
accord
intern
consensu
confer
criteria
defin
comorbid
patholog
anteced
patient
antivir
gap
time
delay
onset
symptom
start
antivir
treatment
multipl
organ
dysfunct
syndrom
mod
shock
defin
follow
intern
criteria
niv
alway
use
arf
earli
stage
failur
niv
defin
patient
intub
invas
ventil
niv
trial
spo
import
respiratori
work
appear
data
analys
use
spss
softwar
chicago
il
usa
data
express
frequenc
percentag
median
interquartil
rang
univari
analysi
qualit
variabl
chisquar
fisher
test
use
quantit
variabl
analys
comparison
mean
student
test
stepwis
multivari
analysi
perform
logist
regress
take
variabl
p
valu
univari
analysi
other
special
clinic
interest
chronic
obstruct
pulmonari
diseas
heart
failur
depend
variabl
p
valu
less
consid
statist
signific
adult
pandem
influenza
viral
pneumonia
admit
icu
fig
show
distribut
studi
popul
depend
ventil
provid
baselin
characterist
noninvas
ventil
patient
compar
subgroup
briefli
describ
tabl
compar
nonventil
subject
patient
success
niv
present
comorbid
versu
p
higher
lactat
dehydrogenas
versu
ul
p
creatin
kians
versu
ul
p
level
well
longer
icu
stay
versu
day
p
tabl
niv
trial
success
patient
fail
requir
intub
invas
mechan
ventil
henc
patient
underw
intub
intub
ventil
begin
intub
ventil
niv
failur
therefor
ventil
patient
admit
icu
influenza
v
pneumonia
benefit
niv
lower
apach
ii
score
median
versu
p
lower
sofa
score
median
versu
p
presenc
fewer
two
chest
xray
quadrant
opac
haemodynam
stabil
analys
absenc
need
vasopressor
absenc
acut
renal
failur
mod
associ
niv
success
tabl
patient
requir
shorter
mechan
ventil
time
median
versu
day
p
shorter
icu
stay
versu
day
p
shorter
hospit
stay
versu
day
p
patient
niv
failur
multivari
analysi
tabl
demonstr
niv
success
associ
presenc
fewer
two
chest
xray
quadrant
opac
vasopressor
requir
moreov
compar
subset
noninvas
ventil
patient
two
quadrant
opac
sofa
score
versu
sofa
success
rate
increas
ci
wherea
sofa
score
success
rate
becam
ci
differ
found
compar
invas
ventil
patient
niv
failur
initi
submit
orotrach
intub
invas
ventil
regard
apach
ii
sofa
score
radiograph
infiltr
proport
shock
ventilatorassoci
pneumonia
icu
hospit
stay
mortal
studi
possibl
associ
complic
delay
intub
niv
failur
patient
compar
patient
intub
niv
failur
intub
icu
admiss
show
significantli
differ
rate
ventilatorassoci
pneumonia
versu
twothird
ventilatorassoci
pneumonia
episod
caus
pseudomona
aeruginosa
acinetobact
baumannii
methicillinresist
staphylococcu
aureu
mortal
rate
icu
similar
patient
fail
niv
intub
invas
ventil
begin
ci
p
length
icu
stay
hospit
stay
also
similar
group
first
larg
multicentr
cohort
studi
suggest
arf
patient
viral
influenza
pneumonia
may
respond
niv
therapi
patient
one
radiolog
quadrant
opac
haemodynam
stabil
plu
sofa
score
like
posit
respons
treatment
moreov
patient
niv
failur
delay
intub
trial
noninvas
mechan
ventil
increas
mortal
use
niv
clinician
larg
cohort
patient
sever
acut
respiratori
infect
provoc
contrast
recommend
mani
guidelin
probabl
base
previou
studi
sever
acut
respiratori
syndrom
pandem
european
societi
intens
care
medicin
esicm
british
thorac
societi
includ
niv
highrisk
procedur
diseas
transmiss
arf
caus
influenza
v
although
shown
intub
associ
higher
risk
viral
particl
transmiss
sever
acut
respiratori
syndrom
nonetheless
report
suggest
niv
use
manag
specif
clinic
case
respiratori
failur
cohort
clinician
use
niv
ventil
patient
correspond
patient
admit
icu
influenza
v
pneumonia
valu
compar
seri
averag
report
case
around
rang
ventil
patient
without
pneumonia
overal
report
includ
total
niv
patient
three
seri
total
patient
assess
efficaci
niv
report
around
rang
none
studi
design
purpos
studi
role
niv
heterogen
lack
standard
criteria
start
niv
obvious
weak
treatment
decis
standard
made
attend
physician
niv
perform
sever
patient
despit
possibl
contraind
ie
haemodynam
instabl
mod
patient
inde
multivari
analysi
identifi
haemodynam
stabil
present
chest
xray
opac
fewer
two
quadrant
independ
factor
associ
niv
success
although
vasopressor
use
per
se
absolut
contraind
niv
data
vasopressor
dosag
lactat
level
could
better
clarifi
aspect
base
sever
ill
sever
patient
undergo
niv
one
main
messag
present
studi
could
niv
offer
critic
ill
patient
acut
respiratori
failur
complic
viral
pneumonia
sever
acut
organ
failur
howev
key
question
happen
patient
fail
niv
must
intub
invas
ventil
whether
delay
realli
detriment
clinic
outcom
studi
report
increas
risk
complic
wors
prognosi
hypoxaem
patient
intub
niv
failur
seri
comparison
invas
ventil
patient
niv
failur
initi
intub
invas
ventil
present
similar
mortal
found
differ
two
popul
main
limit
studi
observ
design
secondari
studi
databas
niv
implement
standard
protocol
first
data
provid
sever
acut
respiratori
failur
patient
includ
studi
instanc
respiratori
rate
pao
fio
paco
ph
differ
use
niv
earli
stage
respiratori
failur
instanc
pao
fio
ratio
late
stage
arf
patient
present
intub
criteria
lack
data
allow
comparison
studi
previou
studi
deal
hypoxaem
respiratori
failur
moreov
icu
admiss
intub
criteria
standard
delay
time
intub
niv
failur
record
reason
niv
techniqu
ventil
protocol
report
comparison
previou
studi
possibl
addit
exclud
lack
statist
differ
incid
ventilatorassoci
pneumonia
patient
intub
begin
intub
niv
failur
result
lack
power
current
sampl
size
patient
risk
failur
niv
method
use
optim
niv
report
anoth
limit
selfreport
site
introduc
risk
select
bia
healthcar
worker
prospect
assess
followup
serolog
safeti
procedur
investig
although
offici
notif
nosocomi
transmit
case
report
use
therapi
techniqu
must
appli
use
secur
measur
recommend
cdc
guidelin
mani
scientif
societi
spite
recommend
use
limit
clinician
use
niv
nearli
half
larg
multicentr
cohort
signific
proport
success
suggest
patient
sever
acut
respiratori
infect
take
benefit
earli
noninvas
oxygen
techniqu
random
clinic
trial
warrant
determin
patient
may
benefit
techniqu
improv
prognosi
help
reduc
healthcar
cost
conclus
clinician
use
niv
patient
influenza
v
viral
pneumonia
admit
icu
treatment
effect
niv
success
patient
present
fewer
two
chest
xray
opac
haemodynam
stabil
sofa
score
niv
failur
associ
mortal
similar
patient
intub
start
dr
masclan
rello
contribut
concept
design
studi
acquisit
data
analysi
interpret
data
manuscript
prepar
guarantor
paper
take
respons
integr
work
whole
dr
socia
marqu
vidaur
lorent
almiral
contribut
acquisit
data
analysi
interpret
data
manuscript
prepar
investig
icu
gteisemyciuc
contribut
acquisit
data
list
appendix
addit
dr
perez
specif
respons
statist
analysi
author
report
potenti
conflict
interest
exist
companiesorgan
whose
product
servic
may
discuss
articl
administr
support
logist
storag
data
fund
resourc
assign
node
director
jordi
rello
ciber
centro
de
investigacion
respiratoria
en
red
en
enfermedad
respiratoria
instituto
de
salud
carlo
iii
madrid
spain
part
pci
neumoniaciber
research
group
inde
gener
dedic
thiago
lisboa
sandra
trefler
mireia
llaurado
rosi
luqu
salari
fund
node
ciber
alejandro
rodriguez
salari
fund
institut
catala
de
la
salut
peak
pandem
greatli
appreci
